JPWO2023122140A5 - - Google Patents

Info

Publication number
JPWO2023122140A5
JPWO2023122140A5 JP2024538278A JP2024538278A JPWO2023122140A5 JP WO2023122140 A5 JPWO2023122140 A5 JP WO2023122140A5 JP 2024538278 A JP2024538278 A JP 2024538278A JP 2024538278 A JP2024538278 A JP 2024538278A JP WO2023122140 A5 JPWO2023122140 A5 JP WO2023122140A5
Authority
JP
Japan
Prior art keywords
partially unsaturated
membered saturated
independently selected
methyl
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501762A (ja
JP2025501762A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/053591 external-priority patent/WO2023122140A1/en
Publication of JP2025501762A publication Critical patent/JP2025501762A/ja
Publication of JP2025501762A5 publication Critical patent/JP2025501762A5/ja
Publication of JPWO2023122140A5 publication Critical patent/JPWO2023122140A5/ja
Pending legal-status Critical Current

Links

JP2024538278A 2021-12-22 2022-12-21 Parp1阻害剤 Pending JP2025501762A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163292903P 2021-12-22 2021-12-22
US63/292,903 2021-12-22
US202263327228P 2022-04-04 2022-04-04
US63/327,228 2022-04-04
US202263403459P 2022-09-02 2022-09-02
US63/403,459 2022-09-02
PCT/US2022/053591 WO2023122140A1 (en) 2021-12-22 2022-12-21 Parp1 inhibitors

Publications (3)

Publication Number Publication Date
JP2025501762A JP2025501762A (ja) 2025-01-23
JP2025501762A5 JP2025501762A5 (https=) 2026-01-06
JPWO2023122140A5 true JPWO2023122140A5 (https=) 2026-01-06

Family

ID=85156997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538278A Pending JP2025501762A (ja) 2021-12-22 2022-12-21 Parp1阻害剤

Country Status (14)

Country Link
US (1) US20250163022A1 (https=)
EP (1) EP4452963A1 (https=)
JP (1) JP2025501762A (https=)
KR (1) KR20240136978A (https=)
AU (1) AU2022420969A1 (https=)
CA (1) CA3241875A1 (https=)
CL (1) CL2024001874A1 (https=)
CO (1) CO2024009571A2 (https=)
CR (1) CR20240296A (https=)
IL (1) IL313727A (https=)
MX (1) MX2024007673A (https=)
PE (1) PE20242004A1 (https=)
TW (1) TW202332438A (https=)
WO (1) WO2023122140A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240208923A1 (en) 2021-03-10 2024-06-27 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc6a19 function
IL315586A (en) * 2022-03-11 2024-11-01 Impact Therapeutics Shanghai Inc Substituted tricyclic compounds as parp inhibitors and the use thereof
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
EP4545531A1 (en) * 2022-06-27 2025-04-30 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Tricyclic compounds and uses thereof
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
JP2025535834A (ja) * 2022-11-02 2025-10-28 スアンズ バイオファーマシューティカル カンパニー,リミテッド 多環式ポリ(adpリボース)ポリメラーゼ選択的阻害剤
JP2025538192A (ja) * 2022-11-10 2025-11-26 上海海和薬物研究開発股▲ふん▼有限公司 縮合三環式parp1阻害剤、その調製方法、および使用
WO2024227026A1 (en) * 2023-04-28 2024-10-31 Synnovation Therapeutics, Inc. Heterocyclic compounds as parp1 inhibitors
CN119462669A (zh) * 2023-08-11 2025-02-18 上海海和药物研究开发股份有限公司 稠合三环类化合物、其药物组合物和用途
WO2025067417A1 (zh) * 2023-09-28 2025-04-03 成都赜灵生物医药科技有限公司 并内酰胺环类化合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2459561A1 (en) * 2009-07-30 2012-06-06 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
CA2937012A1 (en) * 2013-10-23 2015-04-30 Sumitomo Dainippon Pharma Co., Ltd. Fused pyrazole derivative
PH12017502228B1 (en) * 2015-06-09 2022-08-03 Onconic Therapeutics Inc Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
MX2022000711A (es) * 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.

Similar Documents

Publication Publication Date Title
JP7753397B2 (ja) ウェルナー症候群RecQヘリカーゼ(WRN)の阻害に関連する疾患を治療するためのトリアゾロ-ピリミジン類似体
JP7688578B2 (ja) メチオニンアデノシルトランスフェラーゼ2aインヒビターとしての2-オキソキナゾリン誘導体
JP6936823B2 (ja) 抗癌活性及び抗増殖活性を呈する2−アミノピリミジン−6−オン及び類似体
JP7807589B2 (ja) アルキニルキナゾリン化合物
JP2025508702A (ja) キナゾリン化合物、及び変異krasタンパク質の阻害剤としてのその使用
RU2650895C2 (ru) Соединения замещенных пиразолонов и способы использования
TWI757312B (zh) 作為異檸檬酸脫氫酶抑制劑的化合物及其應用
RU2769607C2 (ru) N-ацил-N'-(пиридин-2-ил) карбамиды и их аналоги, проявляющие противораковую и антипролиферативную активность
JP2025535046A (ja) Kras g12c変異タンパク質の複素環阻害剤及びその使用
JP5852678B2 (ja) 抗腫瘍剤の効果増強剤
KR20130129244A (ko) 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
BG106853A (bg) Антагонисти на кортикотропин освобождаващ фактор
WO2014147586A1 (en) 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
JP2020536884A (ja) Fshdの治療のためにdux4および下流遺伝子発現を低減するp38キナーゼ阻害剤
EP4034535B1 (en) Aza-quinoline compounds and uses thereof
JPWO2023122140A5 (https=)
MX2012005463A (es) Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
JP2016523976A (ja) 癌の処置のためのidh2突然変異体阻害剤としての2,4−または4,6−ジアミノピリミジン化合物
WO2016151499A1 (en) Formylated n-heterocyclic derivatives as fgfr4 inhibitors
TW202214630A (zh) 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用
CN120500475A (zh) 包括金属通道激活剂的组合疗法
IL297332B2 (en) Quinoline compounds and preparations for inhibiting ezh2
TWI816693B (zh) 環烯烴取代的雜芳環類化合物及其用途
JPWO2022261250A5 (https=)
WO2023125803A1 (zh) 杂芳环氮氧化合物及其制备方法和应用